Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Authors :: Francesco Izzo
Ugo Pace
Salvatore Tafuto
Rossana Casaretti
Lucrezia Silvestro
A. De Stefano
F. Bianco
Guglielmo Nasti
Mauro Piccirillo
A. Cassata
G. Rosati
Chiara Carlomagno
C. Gallo
Carmela Romano
Paolo Delrio
A. Avallone
E. De Gennaro
Domenico Bilancia
Vittorio Albino
Secondo Lastoria
Alfredo Budillon
Alessandro Ottaiano
Source :: Annals of Oncology. 29:v74
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Bevacizumab
business.industry
Colorectal cancer
Phases of clinical research
Hematology
medicine.disease
FOLFOX
Internal medicine
medicine
In patient
business
Survival analysis
medicine.drug

Full Text Access

Tools